Zimmer Biomet (ZBH) Stock Forecast & Price Target

$92.44 +1.96 (+2.16%)

Closing price 05/6/2025 03:59 PM Eastern

Extended Trading

$92.66 +0.23 (+0.25%)

As of 04:52 AM Eastern

Zimmer Biomet - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 22 Analyst Ratings

Sell
2

Hold
11

Buy
9

Based on 22 Wall Street analysts who have issued ratings for Zimmer Biomet in the last 12 months, the stock has a consensus rating of "Hold." Out of the 22 analysts, 2 have given a sell rating, 11 have given a hold rating, and 9 have given a buy rating for ZBH.

Consensus Price Target

$115.50
24.95% Upside

According to the 22 analysts' twelve-month price targets for Zimmer Biomet, the average price target is $115.50. The highest price target for ZBH is $150.00, while the lowest price target for ZBH is $95.00. The average price target represents a forecasted upside of 24.95% from the current price of $92.44.

Get the Latest News and Ratings for ZBH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zimmer Biomet and its competitors.

ZBH Analyst Ratings Over Time

Type	Current Forecast 5/7/24 to 5/7/25	1 Month Ago 4/7/24 to 4/7/25	3 Months Ago 2/7/24 to 2/6/25	1 Year Ago 5/8/23 to 5/7/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	5 Buy rating(s)
Hold	11 Hold rating(s)	11 Hold rating(s)	11 Hold rating(s)	8 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$115.50	$124.15	$124.11	$135.40
Forecasted Upside	24.95% Upside	18.64% Upside	20.68% Upside	11.50% Upside
Consensus Rating	Hold	Hold	Hold	Hold

ZBH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZBH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zimmer Biomet Stock vs. The Competition

Type	Zimmer Biomet	Medical Companies	S&P 500
Consensus Rating Score	2.32	2.81	2.54
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	24.95% Upside	3,854.29% Upside	18.95% Upside
News Sentiment Rating	Positive News See Recent ZBH News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/6/2025	Stifel Nicolaus 4 of 5 stars	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target	Buy ➝ Buy	$138.00 ➝ $115.00	+27.29%
5/6/2025	The Goldman Sachs Group 3 of 5 stars	David Roman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$120.00 ➝ $104.00	+14.50%
5/6/2025	Raymond James 4 of 5 stars	Jayson Bedford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$119.00 ➝ $104.00	+13.70%
5/6/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$125.00 ➝ $112.00	+22.44%
5/6/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Cecilia Furlong Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$115.00 ➝ $95.00	+4.11%
5/6/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$128.00 ➝ $105.00	+15.83%
5/6/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$113.00 ➝ $98.00	+8.66%
5/6/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jeff Johnson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$130.00 ➝ $115.00	+27.29%
4/14/2025	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
2/10/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold	$118.00 ➝ $113.00	+12.11%
Get the Latest News and Ratings for ZBH and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Zimmer Biomet and its competitors with MarketBeat's FREE daily newsletter.
2/10/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Underweight ➝ Underweight	$118.00 ➝ $112.00	+10.88%
2/7/2025	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Boone Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$140.00 ➝ $140.00	+37.57%
2/7/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
10/15/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$145.00 ➝ $135.00	+29.93%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	In-Line ➝ In-Line	$113.00 ➝ $110.00	+2.31%
9/10/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$120.00 ➝ $115.00	+10.09%
9/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
9/6/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$143.00 ➝ $119.00	+13.61%
8/8/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sell ➝ Sell	$112.00 ➝ $107.00	-0.07%
7/10/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$134.00 ➝ $120.00	+12.25%
7/1/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. O'brien Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$140.00 ➝ $115.00	+5.96%
5/21/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$150.00	+25.89%
10/20/2023	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$120.00	+14.56%
5/18/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/18/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 05:27 AM ET.

Should I Buy Zimmer Biomet Stock? ZBH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, May 5, 2025. Please send any questions or comments about these Zimmer Biomet pros and cons to contact@marketbeat.com.

Zimmer Biomet
Bull Case

Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

The current stock price is around $102.60, which may present a buying opportunity for investors looking for value in the medical equipment sector.
Zimmer Biomet Holdings, Inc. recently reported earnings per share (EPS) of $2.31, slightly exceeding analysts' expectations, indicating strong financial performance.
The company has a solid market capitalization of approximately $20.30 billion, reflecting its significant presence and stability in the medical technology industry.
Institutional investors own about 88.89% of the company's stock, suggesting strong confidence from large financial entities in Zimmer Biomet's future prospects.
Zimmer Biomet has announced a quarterly dividend of $0.24 per share, providing a steady income stream for investors, with a dividend yield of 0.94%.

Zimmer Biomet
Bear Case

Investors should be bearish about investing in Zimmer Biomet Holdings, Inc. for these reasons:

The stock has experienced fluctuations, with a 12-month low of $93.10, indicating potential volatility that could concern risk-averse investors.
Analysts have mixed ratings on the stock, with a consensus rating of "Hold," suggesting uncertainty about its future performance.
Recent insider selling, including a senior vice president selling shares, may raise red flags about the company's short-term outlook.
The price-to-earnings (P/E) ratio of 23.04 may indicate that the stock is overvalued compared to its earnings, which could deter value-focused investors.
Market analysts have set varying price targets, with some lowering their expectations, which could signal a lack of confidence in the stock's growth potential.

ZBH Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Zimmer Biomet is $115.50, with a high forecast of $150.00 and a low forecast of $95.00.
: 22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 2 sell ratings, 11 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ZBH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares.
: According to analysts, Zimmer Biomet's stock has a predicted upside of 24.95% based on their 12-month stock forecasts.
: Zimmer Biomet has been rated by research analysts at Barclays, BTIG Research, JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Raymond James, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Zimmer Biomet less than other "medical" companies. The consensus rating for Zimmer Biomet is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZBH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:ZBH) was last updated on 5/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zimmer Biomet (ZBH) Stock Forecast & Price Target